Investment
Investment
Financial Information
Income Statement
Investment
Financial Information
Income Statement
Income Statement
-
Revenue
-
Operating Profit
-
Net Profit of Current Term
| 2018년 | 2019년 | 2020년 | |
|---|---|---|---|
| Revenue | - | - | - |
| Cost of Sale | - | - | - |
| Gross Margin | - | - | - |
| Selling and Administrative Expenses | 4 | 117 | 1,002 |
| Operating Profit | - 4 | - 117 | - 1,002 |
| Non-operating Profit | - | 1 | 24 |
| Non-operating Expenses | - | - | 1 |
| Premium on Common Stocks | - | 3,993 | 3,993 |
| Net Profit before Income Tax | - 4 | - 117 | - 980 |
| Income Tax | - | - | - |
| Net Profit of Current Term | - 4 | - 117 | - 980 |
Address : CELROS BIOTECH strives to extend life and improve quality of life by developing antibodies targeting inflammatory diseases and new synthetic drugs to inhibit Nox. Tel : 070-4651-4380~1 Fax : 070-8230-4382 E-mail : foever23@celros.com, chn6307@celros.com